This study was performed at the Hebrew University Veterinary Teaching Hospital. Canine pepsinogen-A, C-reactive protein, and canine pancreatic-like immunoreactivity were measured at the Gastrointestinal Laboratory, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University.
Serum Pepsinogen-A, Canine Pancreatic Lipase Immunoreactivity, and C-Reactive Protein as Prognostic Markers in Dogs with Gastric Dilatation-Volvulus
Article first published online: 18 MAY 2012
Copyright © 2012 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 26, Issue 4, pages 920–928, July-August 2012
How to Cite
Israeli, I., Steiner, J., Segev, G., Kass, P.H., Suchodolski, J.S., Sattasathuchana, P., Bruchim, Y., Yudelevitch, S. and Aroch, I. (2012), Serum Pepsinogen-A, Canine Pancreatic Lipase Immunoreactivity, and C-Reactive Protein as Prognostic Markers in Dogs with Gastric Dilatation-Volvulus. Journal of Veterinary Internal Medicine, 26: 920–928. doi: 10.1111/j.1939-1676.2012.00940.x
The study was unsupported.
Results of this study were presented in part at the Annual Israeli Veterinary Symposium, September 2011, Beit Dagan, Israel.
- Issue published online: 13 JUL 2012
- Article first published online: 18 MAY 2012
- Manuscript Accepted: 27 MAR 2012
- Manuscript Revised: 27 FEB 2012
- Manuscript Received: 24 NOV 2011
- Gastric necrosis;
Pepsinogens are proenzymes secreted by gastric chief cells. In humans, their serum concentrations reflect gastric mucosal morphological and functional status.
To evaluate serum canine pepsinogen-A (cPG-A), C-reactive protein (CRP), and canine pancreatic lipase immunoreactivity (cPLI) concentrations in dogs with gastric dilatation-volvulus (GDV).
Sixty-six dogs presented with GDV and 79 healthy controls.
Blood was collected prospectively, and records retrospectively reviewed.
Median cPG-A concentration was higher in GDV dogs (median, 397 μg/L; range, 37–5,410) compared to controls (median, cPG-A 304 μg/L; range, 18–848; P = .07). Mortality rate in GDV dogs was 22.7%. In nonsurvivors of GDV, median cPG-A was higher compared to survivors (median, 746 μg/L; range, 128–5,409 versus median, 346; range, 36–1,575, respectively; P = .003). The proportion of dogs with increased cPG-A increased with gastric wall damage score (P = .007). An ROC analysis of cPG-A as a predictor of death showed an area under the curve (AUC) of 0.75, higher than lactate (AUC 0.66), and corresponded to a sensitivity and specificity of 53% and 88%, respectively. CRP was increased in 48 dogs (75%), cPLI was >200 μg/L in 26 dogs (39.4%) and >400 μg/L in 12 dogs (18.2%) but both analytes had no association with outcome.
Presurgical cPG-A concentration was positively and significantly associated with gastric wall lesion severity, but, based on ROC analysis, it was only a moderate outcome predictor. CRP and cPLI were commonly increased in dogs with GDV.